Company Overview and News

Echo Resources continues to make progress in the Yandal gold belt

Echo Resources (ASX:EAR) is continuing to receive significant gold intersections from drilling at the Empire District in the Yandal gold belt of Western Australia.

Intermin Resources acquires gold project near Kalgoorlie

Intermin Resources (ASX:IRC) has signed a binding agreement to acquire the Anthill gold project located 54 kilometres northwest of Kalgoorlie-Boulder in Western Australia.

Echo Resources strengthens gold portfolio via Metaliko Resources takeover

Echo will now send compulsory acquisition notices to acquire all remaining Metaliko shares not accepted in the takeover bid in accordance with the Corporations Act.

Echo, Metaliko confirm $39m merger

Investors have reacted well to news that gold-focused companies Echo Resources and Metaliko Resources will merge in a deal worth $38.9 million.

Metaliko and Echo in tie-up

Echo Resources and Metaliko Resources are expected to announce a tie-up this week, after the two ASX-listed companies with assets in the eastern Goldfields region announced trading halts today.

Metaliko Resources Ltd in an ASX trading halt

Metaliko Resources Ltd (ASX:MKO) has been granted a trading halt by the ASX, with its shares placed in pre-open. Metaliko requested the halt pending a material transaction. The halt will remain in place until the opening of trade on Friday 30th September 2016, or earlier if an announcement is made to the market.

Metaliko Resources Ltd gearing up to monetise Bronzewing mill

Metaliko Resources Ltd (ASX:MKO)  is focused on advanced gold exploration projects with identified gold mineralization and the potential for further significant discoveries. Metaliko's project portfolio is located in the Eastern Goldfields of Western Australia.

Intermin Resources Ltd buys further gold tenure in WA goldfields

Cashed up Intermin Resources Ltd (ASX:IRC) continues to deliver on a strategy to consolidate the fragmented Menzies to Kalgoorlie corridor in Western Australia, to grow its gold ounce resources. Intermin will issue shares worth $375,000 to Metaliko Resources Ltd (ASX:MKO) to acquire 100% of their tenement package of: four Exploration Licenses, 56 Prospecting Licenses, one miscellaneous License and five Mining Leases covering 141km².

Half Yearly Report and Accounts


Change of Company Phone Number



Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...